Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/235276
Type: Artigo de periódico
Title: Prognostic Significance Of Pd-l1 And Pd-l2 In Breast Cancer.
Author: Baptista, Mauricio Z
Sarian, Luis Otavio
Derchain, Sophie F M
Pinto, Glauce A
Vassallo, José
Abstract: PD-L1 and PD-L2 constitute an important antitumor immune response. In breast cancer, their prognostic value is still to be defined. In this study, we investigate the correlation between PD-L1 and PD-L2 protein expressions with clinical and pathologic features and disease-free survival and overall survival. To assess PD-L1 and PD-L2 expressions, we conducted immunohistochemistry studies using a breast cancer tissue microarray encompassing a total of 192 breast cancer cases, stages I, II, and III, with detailed clinical and outcome data. PD-L1 expression was present in 56.6% (107/189), and PD-L2 expression was identified in 50.8% (97/191) of breast cancer cases. Younger age at diagnosis, lymph node positivity, negative estrogen receptor, and recurrence at distant sites were all associated with both PD-L1 and PD-L2 expressions. The presence of larger tumors was associated only with PD-L1 expression. In our study, PD-L1 expression was significantly associated with better overall survival (P = .04) in breast cancer patients. Despite its association with poor clinical and pathologic features, PD-L1 expression emerges as a positive prognostic biomarker in breast cancer. This survival result might be due to the presence of a strong antitumor immune response leading to PD-L1 expression.
Subject: Biomarker
Breast Cancer
Pd-l1
Pd-l2
Prognosis
Survival
Citation: Human Pathology. v. 47, n. 1, p. 78-84, 2016-Jan.
Rights: embargo
Identifier DOI: 10.1016/j.humpath.2015.09.006
Address: http://www.ncbi.nlm.nih.gov/pubmed/26541326
Date Issue: 2016
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
pmed_26541326.pdf1.43 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.